A CLINICAL CASE OF NON-SMALL CELL THERAPY LUNG CANCER WITH PD-L1 EXPRESSION

Abstract

Immunotherapy by choosing a personalized treatment based on efficacy, favorable toxicity profile and tolerability consistent with the results of randomized clinical trials (KEYNOTE) is a promising new approach to the treatment of metastatic non-small cell lung cancer. Currently, in the treatment of non-small cell lung cancer, the range of immunotherapeutic drugs has significantly expanded, the use of which makes it possible to achieve tumor control while maintaining the quality of life of patients and reducing or absence of clinical symptoms and immuno-mediated adverse events. One of these drugs is Pembrolizumab (a monoclonal antibody that blocks the interaction between PD–1 and its ligands (PD-L1/PD-L2)), which is used in both second and first-line therapy, provided a high level of PD-L1 expression (≥50%). This paper describes a clinical case of a patient with non-small cell lung cancer, with PD-L1 expression, who received immunotherapy with pembrolizumab. During immunotherapy, the patient's cough and chest pain decreased clinically, the quality of life and the duration of partial regression improved by more than 6 months. There were no immunomediated adverse events in the patient during the entire period of treatment and follow-up. The data presented in the article will be useful to oncologists, chemotherapists, oncosurgeons, radiologists, histologists, therapists.